Forge, which launched in July 2020, has been expanding their Columbus, OH, facilities so that the adeno-associated virus gene therapy products the company develops for its clients can go from discovery to development to the commercial cycle in one space.
"We have the means to continue expanding that facility in a significant way," Maslowski said.
Forge also plans to expand its reach into the European market and will have client development offices in Europe to serve clients there, Maslowski added.
In addition to growing the company's reach and capabilities, Forge looks to have more products in development, Tyrpien said.
"We have two therapeutic products in the pipeline, but we are also looking for new technologies to add into this growing development," Tyrpien said.
Watch the video below to learn more.